Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters

B. Nieuwenhuis, E. Laperrousaz, JR. Tribble, J. Verhaagen, JW. Fawcett, KR. Martin, PA. Williams, A. Osborne

. 2023 ; 30 (6) : 503-519. [pub] 20230113

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011310

Grantová podpora
MR/R004463/1 Medical Research Council - United Kingdom
MR/V002694/1 Medical Research Council - United Kingdom
MR/R004544/1 Medical Research Council - United Kingdom

E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 36635457
DOI 10.1038/s41434-022-00380-z
Knihovny.cz E-zdroje

Recombinant adeno-associated viral vectors (AAVs) are an effective system for gene transfer. AAV serotype 2 (AAV2) is commonly used to deliver transgenes to retinal ganglion cells (RGCs) via intravitreal injection. The AAV serotype however is not the only factor contributing to the effectiveness of gene therapies. Promoters influence the strength and cell-selectivity of transgene expression. This study compares five promoters designed to maximise AAV2 cargo space for gene delivery: chicken β-actin (CBA), cytomegalovirus (CMV), short CMV early enhancer/chicken β-actin/short β-globulin intron (sCAG), mouse phosphoglycerate kinase (PGK), and human synapsin (SYN). The promoters driving enhanced green fluorescent protein (eGFP) were examined in adult C57BL/6J mice eyes and tissues of the visual system. eGFP expression was strongest in the retina, optic nerves and brain when driven by the sCAG and SYN promoters. CBA, CMV, and PGK had moderate expression by comparison. The SYN promoter had almost exclusive transgene expression in RGCs. The PGK promoter had predominant expression in both RGCs and AII amacrine cells. The ubiquitous CBA, CMV, and sCAG promoters expressed eGFP in a variety of cell types across multiple retinal layers including Müller glia and astrocytes. We also found that these promoters could transduce human retina ex vivo, although expression was predominantly in glial cells due to low RGC viability. Taken together, this promoter comparison study contributes to optimising AAV-mediated transduction in the retina, and could be valuable for research in ocular disorders, particularly those with large or complex genetic cargos.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011310
003      
CZ-PrNML
005      
20230801132943.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41434-022-00380-z $2 doi
035    __
$a (PubMed)36635457
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Nieuwenhuis, Bart $u John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. bn246@cam.ac.uk $u Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK. bn246@cam.ac.uk $1 https://orcid.org/0000000220652271
245    10
$a Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters / $c B. Nieuwenhuis, E. Laperrousaz, JR. Tribble, J. Verhaagen, JW. Fawcett, KR. Martin, PA. Williams, A. Osborne
520    9_
$a Recombinant adeno-associated viral vectors (AAVs) are an effective system for gene transfer. AAV serotype 2 (AAV2) is commonly used to deliver transgenes to retinal ganglion cells (RGCs) via intravitreal injection. The AAV serotype however is not the only factor contributing to the effectiveness of gene therapies. Promoters influence the strength and cell-selectivity of transgene expression. This study compares five promoters designed to maximise AAV2 cargo space for gene delivery: chicken β-actin (CBA), cytomegalovirus (CMV), short CMV early enhancer/chicken β-actin/short β-globulin intron (sCAG), mouse phosphoglycerate kinase (PGK), and human synapsin (SYN). The promoters driving enhanced green fluorescent protein (eGFP) were examined in adult C57BL/6J mice eyes and tissues of the visual system. eGFP expression was strongest in the retina, optic nerves and brain when driven by the sCAG and SYN promoters. CBA, CMV, and PGK had moderate expression by comparison. The SYN promoter had almost exclusive transgene expression in RGCs. The PGK promoter had predominant expression in both RGCs and AII amacrine cells. The ubiquitous CBA, CMV, and sCAG promoters expressed eGFP in a variety of cell types across multiple retinal layers including Müller glia and astrocytes. We also found that these promoters could transduce human retina ex vivo, although expression was predominantly in glial cells due to low RGC viability. Taken together, this promoter comparison study contributes to optimising AAV-mediated transduction in the retina, and could be valuable for research in ocular disorders, particularly those with large or complex genetic cargos.
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a retinální gangliové buňky $x metabolismus $7 D012165
650    _2
$a aktiny $x genetika $x metabolismus $7 D000199
650    _2
$a transdukce genetická $7 D014161
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a transgeny $7 D019076
650    _2
$a Dependovirus $x genetika $x metabolismus $7 D000229
650    12
$a Parvovirinae $x genetika $7 D019219
650    _2
$a zelené fluorescenční proteiny $x genetika $7 D049452
650    12
$a cytomegalovirové infekce $x genetika $x metabolismus $7 D003586
650    _2
$a genetické vektory $x genetika $7 D005822
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Laperrousaz, Elise $u John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK $1 https://orcid.org/0000000283428533
700    1_
$a Tribble, James R $u Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000183017358
700    1_
$a Verhaagen, Joost $u Laboratory for Regeneration of Sensorimotor Systems, Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences (KNAW), Amsterdam, The Netherlands $u Centre for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
700    1_
$a Fawcett, James W $u John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK $u Centre of Reconstructive Neuroscience, Institute of Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000279904568 $7 mub2018979500
700    1_
$a Martin, Keith R $u John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK $u Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia $u Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, VIC, Australia
700    1_
$a Williams, Pete A $u Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000161948397
700    1_
$a Osborne, Andrew $u John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. ao@ikarovec.com $u Ikarovec Ltd, The Norwich Research Park Innovation Centre, Norwich, UK. ao@ikarovec.com $1 https://orcid.org/0000000256492337
773    0_
$w MED00001890 $t Gene therapy $x 1476-5462 $g Roč. 30, č. 6 (2023), s. 503-519
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36635457 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132940 $b ABA008
999    __
$a ok $b bmc $g 1963611 $s 1197575
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 30 $c 6 $d 503-519 $e 20230113 $i 1476-5462 $m Gene therapy $n Gene Ther $x MED00001890
GRA    __
$a MR/R004463/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a MR/V002694/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a MR/R004544/1 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace